Literature DB >> 10532640

Kinetic modeling of N-[11C]methylpiperidin-4-yl propionate: alternatives for analysis of an irreversible positron emission tomography trace for measurement of acetylcholinesterase activity in human brain.

R A Koeppe1, K A Frey, S E Snyder, P Meyer, M R Kilbourn, D E Kuhl.   

Abstract

N-[11C]Methylpiperidin-4-yl propionate ([11C]PMP) is a substrate for hydrolysis by acetylcholinesterase (AChE). This work evaluates kinetic analysis alternatives for estimation of relative AChE activity using dynamic positron emission tomography (PET) studies of [11C]PMP. The PET studies were performed on three groups of subjects: (1) 12 normal volunteer subjects, aged 20 to 45 years, who received a single intravenous injection of 16 to 32 mCi of [11C]PMP; (2) six subjects, aged 21 to 44 years, who received two 16-mCi injections of [11C]PMP (baseline and visual stimulation, respectively); and (3) five subjects, aged 24 to 40 years, who received two 16-mCi injections separated by 200 minutes (baseline and after a 1-hour constant infusion of 1.5 mg of physostigmine, respectively). Dynamic acquisition consisted of a 17-frame sequence over 80 minutes. All analysis methods were based on a first-order kinetic model consisting of two tissue compartments with the parameter k3, representing PMP hydrolysis, being the index of AChE activity. Four different schemes were used to estimate k3: (1) an unconstrained non-linear least-squares fit estimating blood-brain barrier transport parameters, K1 and k2, in addition to the hydrolysis rate constant k3; (2) and (3), two methods of constraining the fit by fixing the volume of distribution of free tracer (DVfree); and (4), a direct estimation of k3 without use of an arterial input function based on the shape of the tissue time-activity curve alone. Results showed that k3 values from the unconstrained fitting and no input methods were estimated with similar accuracy, whereas the two methods using DVfree constraints yielded similar results. The authors conclude that the optimal analysis method for [11C]PMP differs as a function of AChE activity. All four methods gave precise measures of k3 in regions with low AChE activity (approximately 10% coefficient of variation in cortex), but surprisingly, with unconstrained methods yielding estimates with lower variability than constrained methods. In regions with moderate to high AChE activity, constrained methods were required to yield meaningful estimates and were superior to the unconstrained methods.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10532640     DOI: 10.1097/00004647-199910000-00012

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  28 in total

1.  First demonstration of in vivo mapping for regional brain monoacylglycerol lipase using PET with [11C]SAR127303.

Authors:  Tomoteru Yamasaki; Wakana Mori; Yiding Zhang; Akiko Hatori; Masayuki Fujinaga; Hidekatsu Wakizaka; Yusuke Kurihara; Lu Wang; Nobuki Nengaki; Tomoyuki Ohya; Steven H Liang; Ming-Rong Zhang
Journal:  Neuroimage       Date:  2018-05-05       Impact factor: 6.556

2.  An improved radiosynthesis of O-(2-[18 F]fluoroethyl)-O-(p-nitrophenyl)methylphosphonate: A first-in-class cholinesterase PET tracer.

Authors:  Kiel D Neumann; Charles M Thompson; Joseph E Blecha; John M Gerdes; Henry F VanBrocklin
Journal:  J Labelled Comp Radiopharm       Date:  2017-05-15       Impact factor: 1.921

3.  Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer's disease.

Authors:  N I Bohnen; D I Kaufer; R Hendrickson; L S Ivanco; B J Lopresti; R A Koeppe; C C Meltzer; G Constantine; J G Davis; C A Mathis; S T Dekosky; R Y Moore
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-03       Impact factor: 10.154

4.  Mapping human brain fatty acid amide hydrolase activity with PET.

Authors:  Pablo M Rusjan; Alan A Wilson; Romina Mizrahi; Isabelle Boileau; Sofia E Chavez; Nancy J Lobaugh; Stephen J Kish; Sylvain Houle; Junchao Tong
Journal:  J Cereb Blood Flow Metab       Date:  2012-12-05       Impact factor: 6.200

5.  Cerebral cortical and subcortical cholinergic deficits in parkinsonian syndromes.

Authors:  S Gilman; R A Koeppe; B Nan; C-N Wang; X Wang; L Junck; R D Chervin; F Consens; A Bhaumik
Journal:  Neurology       Date:  2010-05-04       Impact factor: 9.910

Review 6.  Positron emission tomography studies of organophosphate chemical threats and oxime countermeasures.

Authors:  Charles M Thompson; John M Gerdes; Henry F VanBrocklin
Journal:  Neurobiol Dis       Date:  2019-04-22       Impact factor: 5.996

7.  Early initiation of hormone therapy in menopausal women is associated with increased hippocampal and posterior cingulate cholinergic activity.

Authors:  Yolanda R Smith; Luvina Bowen; Tiffany M Love; Alison Berent-Spillson; Kirk A Frey; Carol C Persad; Nancy K Reame; Robert A Koeppe; Jon-Kar Zubieta
Journal:  J Clin Endocrinol Metab       Date:  2011-08-24       Impact factor: 5.958

8.  Cognitive correlates of cortical cholinergic denervation in Parkinson's disease and parkinsonian dementia.

Authors:  N I Bohnen; D I Kaufer; R Hendrickson; L S Ivanco; B J Lopresti; G M Constantine; Ch A Mathis; J G Davis; R Y Moore; S T Dekosky
Journal:  J Neurol       Date:  2005-09-02       Impact factor: 4.849

Review 9.  Molecular Imaging of the Cholinergic System in Parkinson's Disease.

Authors:  Nicolaas I Bohnen; Prabesh Kanel; Martijn L T M Müller
Journal:  Int Rev Neurobiol       Date:  2018-09-20       Impact factor: 3.230

10.  Initial evaluation of 11C-DPA-713, a novel TSPO PET ligand, in humans.

Authors:  Christopher J Endres; Martin G Pomper; Michelle James; Ovsev Uzuner; Dima A Hammoud; Crystal C Watkins; Aaron Reynolds; John Hilton; Robert F Dannals; Michael Kassiou
Journal:  J Nucl Med       Date:  2009-07-17       Impact factor: 10.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.